Table 1.
Selected baseline characteristics of the matched OAB AC users and nonusers
| Variable | Non-OAB AC users | OAB AC users | p value |
|---|---|---|---|
| (n = 782) | (n = 782) | ||
| General characteristics | |||
| Mean age at initial visit, yr (SD) | 74.1 (9.0) | 74.7 (8.4) | 0.196 |
| Male, n (%) | 302 (38.6) | 303 (38.7) | 0.959 |
| Mean time between baseline and FU visits, d (SD) | 434 (138) | 455 (165) | 0.070 |
| Cognitive status at study visit, n (%) | |||
| Normal cognition | 393 (50.3) | 393 (50.3) | 1.000 |
| Mild cognitive impairment | 173 (22.1) | 173 (22.1) | |
| Dementia | 216 (27.6) | 216 (27.6) | |
| Education, n (%) | |||
| <12 yr | 45 (5.8) | 51 (6.5) | 0.496 |
| 12–13 yr | 200 (25.6) | 200 (25.6) | |
| 14–16 yr | 251 (32.1) | 263 (33.6) | |
| ≥17 yr | 286 (36.6) | 266 (34.0) | |
| Visual impairment, n (%) | 234 (29.9) | 256 (32.7) | 0.484 |
| Hearing impairment, n (%) | 582 (74.4) | 572 (73.1) | 0.751 |
| Living situation, n (%) | |||
| Lives alone | 202 (25.8) | 209 (26.7) | 0.445 |
| Lives with spouse or partner | 506 (64.7) | 492 (62.9) | |
| Lives with relative or friend | 60 (7.7) | 56 (7.2) | |
| Other | 14 (1.8) | 25 (3.2) | |
| Medication use, n (%) | |||
| Antihypertensives | 433 (55.4) | 444 (56.8) | 0.575 |
| Antiadrenergic agent | 84 (10.7) | 82 (10.5) | 0.870 |
| Calcium channel blocking agent | 129 (16.5) | 141 (18.0) | 0.422 |
| Diuretic | 100 (12.8) | 120 (15.3) | 0.146 |
| Lipid lowering medication | 356 (45.5) | 358 (45.8) | 0.919 |
| Anticoagulant or antiplatelet agent | 272 (34.8) | 277 (35.4) | 0.791 |
| Antidepressant | 224 (28.6) | 233 (29.8) | 0.617 |
| Antipsychotic agent | 16 (2.0) | 21 (2.7) | 0.405 |
| Anxiolytic, sedative, or hypnotic agent | 98 (12.5) | 105 (13.4) | 0.598 |
| Alzheimer’s disease medications | 206 (26.3) | 202 (25.8) | 0.818 |
| Anti-Parkinson agent | 58 (7.4) | 53 (6.8) | 0.622 |
| Estrogen hormone therapy | 38 (4.9) | 35 (4.5) | 0.719 |
| Diabetes medication | 83 (10.6) | 82 (10.5) | 0.934 |
| APOE genotype, n (%) | |||
| ε3/ε3 | 396 (50.6) | 390 (49.9) | 0.995 |
| ε3/ε4 | 242 (30.9) | 245 (31.3) | |
| ε3/ε2 | 73 (9.3) | 77 (9.8) | |
| ε4/ε4 | 49 (6.3) | 47 (6.0) | |
| ε4/ε2 | 20 (2.6) | 20 (2.6) | |
| ε2/ε2 | 2 (0.3) | 3 (0.4) |
AC = anticholinergic; FU = follow-up; OAB = overactive bladder.